Login to Your Account

Circassia Pharma lands commercial rights for Astrazeneca COPD drugs

By Michael Fitzhugh
Staff Writer

Monday, March 20, 2017

Circassia Pharmaceuticals plc has agreed to pay Astrazeneca plc up to $230 million in cash and stock to lead U.S. promotion of two chronic obstructive pulmonary disease (COPD) therapies in a deal that Circassia CEO Steve Harris told BioWorld Today will immediately add a second product to its portfolio and drive a short-order doubling of its sales force to 200 reps.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription